F-Prime Capital

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

Bluebird Kids Health is a pediatric healthcare provider that aims to build a healthier future for children. It offers a value-based care model, delivering comprehensive, evidence-based care tailored to each family's needs. Services include nutrition support, sleep training, treatments for common ailments like rashes and viruses, all aimed at reducing medical costs and providing personalized care. The company is also developing a proprietary technology platform, enhanced by AI, to proactively manage and coordinate treatment, further simplifying the experience for its clinical team.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Based on our deep science and focused on patients in need.

Shift Bioscience employs simulation-guided techniques to identify safer gene factors for cellular rejuvenation, aiming to develop a drug family that treats multiple age-related diseases. Its high-throughput aging biomarker enables accurate cell simulations, with the goal of making full health in old age accessible via prescription.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Amber Therapeutics specializes in developing advanced bioelectronic therapies that can sense and adapt, aiming to enhance clinical outcomes for patients with functional disorders of the peripheral nervous system.

Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Founded in 2019, Engrail Therapeutics is dedicated to developing and commercializing neuro drugs. Its primary focus is on treating diseases related to the nervous system. The company's flagship compound, ENX-101, is a preclinical modulator of a receptor for GABA, a neurotransmitter in the brain.

HiLabs is a developer of a healthcare data mining platform that aims to enhance data-driven decision-making within healthcare organizations. By leveraging artificial intelligence, HiLabs empowers employees to explore their data intuitively, uncover novel insights, and interact with data visualizations. The platform allows users to customize dashboards and generate new attributes, thus enhancing their ability to understand and utilize client health data effectively. HiLabs recognizes that healthcare providers possess vital domain knowledge but often lack the necessary tools to extract meaningful insights from their data. Through its innovative solutions, HiLabs bridges this gap, enabling healthcare organizations to harness their data more efficiently and improve overall decision-making processes.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

PlasmaGen Biosciences Pvt. Ltd., established in 2010 and based in Bengaluru, India, is a biopharmaceutical company specializing in plasma protein therapies. The company manufactures a range of products including PlasmaGlob and AlbuMax, brands of Normal Human Immunoglobulin for Intravenous use, PlasmaRho-D I.V. for Rh immunization suppression, PlasmaRAB for rabies infection prophylaxis, PlasmaHep for hepatitis B exposure, VerBumin for conditions like hypovolemic shock and burns, and Gammafact-VIII. These products cater to various medical fields such as hematology, oncology, immunology, pediatrics, rheumatology, dermatology, and neurology. The company serves clinicians, medical practitioners, corporate hospitals, and government institutions.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

ARTBIO is a biotechnology company developing a new class of alpha radioligand medicines for cancer treatment. It focuses on radioligand therapy, delivering alpha or beta emitters to target and destroy cancer cells.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

Doceree is a healthcare marketing technology company that provides a platform and solutions to help pharmaceutical and healthcare brands reach healthcare professionals. Its programmatic platform supports physician engagement and targeted advertising across physician networks, medical journals, telemedicine platforms, and relevant digital channels, delivering compliant, scalable messages. The platform uses artificial intelligence, data segmentation, and analytics to identify target healthcare professionals and optimize reach across global digital ecosystems. Doceree serves pharmaceutical brands, medical device brands, consumer health brands, hospitals, and media agencies, enabling access to physician-only environments and enabling compliant engagement at scale.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Nvelop Therapeutics develops programmable delivery systems for in vivo gene editing and therapeutic cargo delivery. It combines epigenetic editing technologies with next-generation delivery methods to address unmet medical needs. The company focuses on genetic medicines designed to target cells and tissues within the body, aiming to treat severe genetic diseases by delivering gene-editing payloads to therapeutically relevant sites. Early efforts are aligned with enabling editing in cells and tissues that have been difficult to reach, with the objective of expanding the range of actionable genetic therapies. The company seeks to advance in vivo approaches that can improve precision and safety in delivering therapeutic cargo to patients.

Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

K36 Therapeutics develops small molecule therapeutics for cancer treatment. It translates epigenetic modulation of oncogenic pathways into small molecule therapies.

ARTBIO is a biotechnology company developing a new class of alpha radioligand medicines for cancer treatment. It focuses on radioligand therapy, delivering alpha or beta emitters to target and destroy cancer cells.

Adcentrx Therapeutics is a biotechnology company focused on protein conjugate therapeutics for cancer and other life-threatening diseases. The company seeks to accelerate breakthroughs in this field by combining the targeting precision of biologics with the potency of small-molecule payloads, enabling next-generation targeted therapies and expanding treatment options for patients.

Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

RIGImmune is a biopharmaceutical company dedicated to developing innovative immune-modulating therapies targeting RNA virus diseases and enhancing antitumor immune responses. The company focuses on creating novel treatments aimed at addressing a wide range of conditions associated with viral infections and certain cancers. Its therapeutic candidates are designed to improve treatment outcomes for viral respiratory infections, serving as adjuvants or boosters for healthcare providers. By advancing its research and development efforts, RIGImmune aims to contribute significantly to the treatment landscape for both viral and oncological diseases.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.

Doceree is a healthcare marketing technology company that provides a platform and solutions to help pharmaceutical and healthcare brands reach healthcare professionals. Its programmatic platform supports physician engagement and targeted advertising across physician networks, medical journals, telemedicine platforms, and relevant digital channels, delivering compliant, scalable messages. The platform uses artificial intelligence, data segmentation, and analytics to identify target healthcare professionals and optimize reach across global digital ecosystems. Doceree serves pharmaceutical brands, medical device brands, consumer health brands, hospitals, and media agencies, enabling access to physician-only environments and enabling compliant engagement at scale.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.

K36 Therapeutics develops small molecule therapeutics for cancer treatment. It translates epigenetic modulation of oncogenic pathways into small molecule therapies.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

AppliedVR is a Los Angeles‑based company that develops virtual reality therapeutic devices for pain and anxiety management in healthcare settings. Founded in 2013, it partners with institutions such as Cedars‑Sinai and Children’s Hospital Los Angeles to deliver its VR platform in hospitals, surgery centers, and exam rooms across the United States. The company’s flagship product, EaseVRx, is the first VR‑based prescription therapeutic to receive FDA Breakthrough Device Designation; it combines cognitive behavioral therapy and mindfulness to help patients alter pain perception and build coping skills. EaseVRx is self‑administered at home, enabling remote care and improving access, equity, and efficiency in chronic pain treatment. AppliedVR’s clinically validated, on‑demand platform supports both acute and chronic pain, promotes non‑drug pain management, and assists clinicians in achieving better long‑term patient outcomes.

Notable is an artificial intelligence platform for healthcare operations that automates administrative and operational tasks within health systems, clinics, and other care settings. The platform handles patient intake, scheduling, prior authorization, documentation, and billing automation, enabling providers and staff to streamline workflows and reduce manual workload for more efficient care delivery. It is deployed at over 10,000 sites of care and automates a million repetitive workflows daily across Registration and Intake, Scheduling and Referrals, Assistant, Authorizations, Care Gap Closure, and HCC Chart Review, leading to faster patient processing, improved care coordination, and stronger financial performance for healthcare organizations.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Orient Speech Therapy Center specializes in providing professional speech and language therapy services for children facing communication challenges, including those with autism or speech disorders. The center focuses on the early screening, clinical diagnosis, and therapeutic interventions essential for improving children's speech and social skills. It offers a range of refined curricula designed specifically for young learners, including the Star Curriculum, phonics and oral muscle courses, expression courses, and exercise classes. Through these structured programs, Orient Speech Therapy Center aims to enhance the communicative abilities of children, enabling them to express themselves more effectively and engage socially.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Protenus, Inc. is a healthcare compliance analytics company based in Baltimore, Maryland, which was founded in 2014. The company specializes in an AI-driven platform designed to audit access to patient records across health systems in the United States. Protenus' technology identifies risks such as inappropriate access to patient data and the misuse of controlled substances by healthcare staff. By automating the detection of policy violations and other anomalous behaviors, the platform supports healthcare organizations in protecting patient privacy and reducing operational risks. Protenus is recognized for its innovation and commitment to fostering safe patient outcomes while enhancing the reputation of healthcare providers. The company has received accolades such as being named one of America's Best Startup Employers by Forbes and recognized as a Great Place to Work.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.

Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

AppliedVR is a Los Angeles‑based company that develops virtual reality therapeutic devices for pain and anxiety management in healthcare settings. Founded in 2013, it partners with institutions such as Cedars‑Sinai and Children’s Hospital Los Angeles to deliver its VR platform in hospitals, surgery centers, and exam rooms across the United States. The company’s flagship product, EaseVRx, is the first VR‑based prescription therapeutic to receive FDA Breakthrough Device Designation; it combines cognitive behavioral therapy and mindfulness to help patients alter pain perception and build coping skills. EaseVRx is self‑administered at home, enabling remote care and improving access, equity, and efficiency in chronic pain treatment. AppliedVR’s clinically validated, on‑demand platform supports both acute and chronic pain, promotes non‑drug pain management, and assists clinicians in achieving better long‑term patient outcomes.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Cohort, Inc. is a software company focused on enhancing chronic care management and clinical trial processes. Based in New York with an additional office in San Francisco, the company utilizes clinical artificial intelligence and natural language processing to analyze electronic health records. This analysis includes evaluating diagnostics, medications, and clinical notes to provide context relevant to specific patients and their conditions. Cohort’s software streamlines the identification and enrollment of eligible patients, generates tailored care plans, and automates compliance and billing tasks. The company’s solutions are designed to enable Primary Care Providers to improve the scale, efficiency, and outcomes of their Chronic Care Management programs while facilitating clinical trial identification and enrollment.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

J-Pharma specializes in developing novel pharmaceuticals based on a human-genomic approach. Its intellectual property focuses on cell membrane transporters linked to various diseases, enabling the creation of targeted drugs and diagnostic methods. The company aims to improve global health and enhance quality of life for aging populations by generating new drug agents.

Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to discovering and developing targeted therapies for rare disorders, particularly focusing on neurofibromatosis type 1 and related conditions. The company specializes in addressing diseases driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, including cutaneous neurofibromas and other conditions such as immunosuppressant-mediated squamous cell carcinoma and congenital birthmarks. NFlection Therapeutics is known for its innovative approach to drug formulation, offering treatments in a cosmetically elegant gel that can be applied topically, allowing for localized suppression of the Ras pathway while minimizing systemic side effects associated with oral medications. Established in 2014, the company is headquartered in Wayne, Pennsylvania.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Founded in 2016, Owkin is a French-American startup that uses artificial intelligence to enhance medical research. It develops machine learning tools to understand complex biology, identify new treatments, de-risk clinical trials, and develop diagnostics. Owkin's focus is improving drug discovery processes and patient outcomes.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

WelbeHealth serves frail seniors through its PACE (Program of All-Inclusive Care for the Elderly) model, providing comprehensive medical and social care. This enables participants to live better, longer, and more independently. The company coordinates various aspects of care, including medical appointments, therapy sessions, transportation, meals, and personal care services.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Protenus, Inc. is a healthcare compliance analytics company based in Baltimore, Maryland, which was founded in 2014. The company specializes in an AI-driven platform designed to audit access to patient records across health systems in the United States. Protenus' technology identifies risks such as inappropriate access to patient data and the misuse of controlled substances by healthcare staff. By automating the detection of policy violations and other anomalous behaviors, the platform supports healthcare organizations in protecting patient privacy and reducing operational risks. Protenus is recognized for its innovation and commitment to fostering safe patient outcomes while enhancing the reputation of healthcare providers. The company has received accolades such as being named one of America's Best Startup Employers by Forbes and recognized as a Great Place to Work.

Buoy Health is a health technology company that develops AI-powered digital health tools to help individuals manage healthcare options. It offers an online healthcare assistant that analyzes symptoms, performs first-line triage, and provides treatment recommendations. Its platform delivers real-time symptom analysis and helps users navigate the healthcare system, research benefits, and locate in-network providers. For employers, the platform surfaces benefits information, guides employees to in-network providers, and integrates with other health portals. Founded in 2014 and based in Boston, Buoy Health aims to resemble a physician-patient conversation through machine learning and proprietary data, enabling users to make informed care decisions.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Founded in 2016, Owkin is a French-American startup that uses artificial intelligence to enhance medical research. It develops machine learning tools to understand complex biology, identify new treatments, de-risk clinical trials, and develop diagnostics. Owkin's focus is improving drug discovery processes and patient outcomes.

TreeENT Health is a specialized healthcare provider focused on ear, nose, and throat (ENT) services, established in 2017 and headquartered in Hangzhou, China. The company operates a chain of medical centers that cater to a variety of ENT conditions, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. TreeENT Health utilizes advanced medical technologies, such as minimally invasive surgical techniques, internet-enabled services, and wearable medical devices, to enhance patient care. Their offerings include diagnostic services like Danish ear hearing detection, nasal endoscopy video examinations, and nasopharyngoscopy, along with personalized chronic disease rehabilitation. The integration of online appointment scheduling through platforms like WeChat facilitates convenient access to expert consultations and treatments, ensuring a high-quality experience for patients.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases characterized by high unmet medical needs. Incorporated in 2016 and based in Oakland, California, the company is known for its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapy specifically targets thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance and increasing mitochondrial DNA copy number, Modis Therapeutics' approach seeks to enhance cellular function and prolong the lives of affected patients. As of September 2019, Modis Therapeutics operates as a subsidiary of Zogenix, Inc.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Notable is an artificial intelligence platform for healthcare operations that automates administrative and operational tasks within health systems, clinics, and other care settings. The platform handles patient intake, scheduling, prior authorization, documentation, and billing automation, enabling providers and staff to streamline workflows and reduce manual workload for more efficient care delivery. It is deployed at over 10,000 sites of care and automates a million repetitive workflows daily across Registration and Intake, Scheduling and Referrals, Assistant, Authorizations, Care Gap Closure, and HCC Chart Review, leading to faster patient processing, improved care coordination, and stronger financial performance for healthcare organizations.

WelbeHealth serves frail seniors through its PACE (Program of All-Inclusive Care for the Elderly) model, providing comprehensive medical and social care. This enables participants to live better, longer, and more independently. The company coordinates various aspects of care, including medical appointments, therapy sessions, transportation, meals, and personal care services.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.